TY - JOUR
T1 - Comprehensive risk score of the E-PASS as a prognostic indicator for patients after elective and emergency curative colorectal cancer surgery
T2 - A multicenter retrospective study
AU - Kato, Yujin
AU - Shigeta, Kohei
AU - Tajima, Yuki
AU - Kikuchi, Hiroto
AU - Hirata, Akira
AU - Nakadai, Jumpei
AU - Sugiura, Kiyoaki
AU - Seo, Yuki
AU - Kondo, Takayuki
AU - Okui, Jun
AU - Matsui, Shimpei
AU - Seishima, Ryo
AU - Okabayashi, Koji
AU - Kitagawa, Yuko
N1 - Funding Information:
Dr. Kitagawa reports grants and personal fees from Chugai Pharmaceutical Co., Ltd.; grants and personal fees from Taiho Pharmaceutical Co. , Ltd.; grants from Yakult Honsha Co. Ltd.; grants and personal fees from Asahi Kasei Co., Ltd.; grants from Otsuka Pharmaceutical Co., Ltd.; grants from Takeda Pharmaceutical Co., Ltd.; grants from Ono Pharmaceutical Co., Ltd.; grants from Tsumura & Co.; grants from Kyouwa Hakkou Kirin Co., Ltd.; grants from Dainippon Sumitomo Pharma Co., Ltd.; grants from EA Pharma Co., Ltd.; grants from Astellas Pharma Inc.; grants from Toyama Chemical Co., Ltd.; grants from Medicon Inc.; grants from Kaken Pharmaceutical Co., Ltd.; grants from Eisai Co., Ltd.; grants and personal fees from Otsuka Pharmaceutical Factory Inc.; grants from Teijin Pharma Limited; grants from Nihon Pharmaceutical Co., Ltd.; grants and personal fees from Nippon Covidien Inc.; and personal fees from Shionogi & Co., Ltd., outside the submitted work.
Publisher Copyright:
© 2022 IJS Publishing Group Ltd
PY - 2022/5
Y1 - 2022/5
N2 - Objective: To evaluate the prognostic value of the comprehensive risk score (CRS) of the Estimation of Physiologic Ability and Surgical Stress for managing patients with colorectal cancer (CRC) who underwent elective and emergency colorectal cancer surgery with curative intent. Summary background data: CRS, which is calculated based on both clinical and surgical factors, is a good predictor of postoperative complications and mortality. However, the impact of CRS in CRC prognosis remains unclear. Methods: Patients with CRC who underwent curative resection between 2010 and 2019 were retrospectively enrolled in this study. The cohort was divided into the low and high CRS groups. The prognostic value of CRS was evaluated via Cox regression and Kaplan–Meier analyses. The CRS cutoff value was obtained using the Youden index applied to OS curves and have not been validated by any validation cohorts. Results: In total, 2407 patients, including 1359 and 1048 patients with low and high CRS, respectively, were enrolled in this study. Multivariate analysis revealed that a CRS was an independent prognostic factor of overall and recurrence-free survival regardless of disease stage. Furthermore, adjuvant chemotherapy was beneficial for the survival of patients with stage III CRC in both high and low CRS groups; however, the survival benefit was limited in elderly high CRS patients. Conclusions: CRS was a strong prognostic factor for CRC regardless of disease stage and might be considered as a biomarker for selecting elderly patients who are eligible for adjuvant chemotherapy.
AB - Objective: To evaluate the prognostic value of the comprehensive risk score (CRS) of the Estimation of Physiologic Ability and Surgical Stress for managing patients with colorectal cancer (CRC) who underwent elective and emergency colorectal cancer surgery with curative intent. Summary background data: CRS, which is calculated based on both clinical and surgical factors, is a good predictor of postoperative complications and mortality. However, the impact of CRS in CRC prognosis remains unclear. Methods: Patients with CRC who underwent curative resection between 2010 and 2019 were retrospectively enrolled in this study. The cohort was divided into the low and high CRS groups. The prognostic value of CRS was evaluated via Cox regression and Kaplan–Meier analyses. The CRS cutoff value was obtained using the Youden index applied to OS curves and have not been validated by any validation cohorts. Results: In total, 2407 patients, including 1359 and 1048 patients with low and high CRS, respectively, were enrolled in this study. Multivariate analysis revealed that a CRS was an independent prognostic factor of overall and recurrence-free survival regardless of disease stage. Furthermore, adjuvant chemotherapy was beneficial for the survival of patients with stage III CRC in both high and low CRS groups; however, the survival benefit was limited in elderly high CRS patients. Conclusions: CRS was a strong prognostic factor for CRC regardless of disease stage and might be considered as a biomarker for selecting elderly patients who are eligible for adjuvant chemotherapy.
KW - Adjuvant chemotherapy
KW - Colorectal cancer
KW - Comprehensive risk score
KW - Estimation of physiologic ability and surgical stress
KW - Prognostic outcome
UR - http://www.scopus.com/inward/record.url?scp=85128680206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128680206&partnerID=8YFLogxK
U2 - 10.1016/j.ijsu.2022.106631
DO - 10.1016/j.ijsu.2022.106631
M3 - Article
C2 - 35447361
AN - SCOPUS:85128680206
SN - 1743-9191
VL - 101
JO - International Journal of Surgery
JF - International Journal of Surgery
M1 - 106631
ER -